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Receipt of opioid prescriptions in pediatric and young adult 
patients may be a risk factor for future opioid misuse. Data 
from prescription drug monitoring programs provide insight 
on outpatient opioid use. In our study, we analyzed the opioid 
dispensing rates for pediatrics and young adults in California. 
Methods
A secondary analysis was performed from 2015-2019 using 
Controlled Utilization Review and Evaluation System data. This 
database provides dispensing data of controlled substances in 
California. Patients younger than 25 years who were prescribed 
opiates were analyzed by county. We further divided them into 
two groups (children: ≤14 years; adolescents and young adult: 
15-24 years). Descriptive statistics and heat maps were used to 
illustrate the trends in opioid usage among different age groups.
Results
The overall percentages for the number of opioids being 
dispensed to patients aged <25 years have decreased over 
the past four years. In 2015, 6 out of 58 counties in California 
were considered “high-rate” with >2.9% of opioids dispensed 
to patients younger than 25 years old; in 2019, this number 
reduced to zero. Patients 25 and older received a higher 
proportion of opioids compared to younger populations; in 
2019, 35.91% of opioids were dispensed to patients 45-64, 
and 8.92% to patients younger than 25.
Conclusion
Pediatric opioid prescriptions have declined over the recent 
years. However, a high degree of variability of prescription 
rates between demographic counties was noted. More studies 
are warranted in order to understand this discrepancy in 
opioid prescribing among pediatric and young adult patients. 
Introduction
The opioid epidemic has been widely viewed as a serious 
public health problem that has been focused primarily on 
adults in the US. However, a similar pattern of increased 
prescribing rates of opioids in adolescents and young adults 
have also been noted.(1,2) This pattern of opioid use in this 
patient population has contributed to increased reports of 
accidental poisoning, misuse and abuse, overdose-related 
hospitalizations, and death.(3-5) From 1999-2016, the pediatric 
mortality rate increased by 268% in children and adolescents 
due to opioids.(6) In an effort to enhance consistency in the 
prescribing of opioids, the CDC published its first guidelines 
regarding the use of opioids in 2016.(7) Since the release of 
these guidelines, national opioid use in this population has 
declined significantly.(8,9)
Opioids are commonly used in the pediatric pain management 
paradigm. In an earlier cross-sectional observational study, 
64% of clinicians were reported to have prescribed an opioid 
to manage acute pain in pediatric patients.(10) Managing opioid 
usage in children needs to be personally tailored and monitored 
closely due to the developmental changes in young children 
and adolescents. Their unique developmental characteristics 
result in the distinct pharmacodynamic and pharmacokinetic 
features which differ from those seen in adults.(11) Although 
guidelines exist for opioid prescription in pediatrics(12-14), the 
resources and training provided to healthcare professionals 
are limited. This makes pain management in the pediatric 
population more challenging, especially in outpatient settings, 
and often leaves prescribers to rely on their clinical judgment 
and experience when prescribing opioids.(2,15)
There has been a significant pullback from opioid prescribing 
in both adults and pediatric patients. From 2012 until 2018, 
the overall opioid prescribing rates fell from 81.3 to 51.5 
prescriptions per 100 persons.(8) With the heightened attention 
being placed on the use of opioids overall and growing 
concerns over the use of opioids within pediatric and young 
adult populations, there is a growing number of research studies 
being published. However, few studies to-date have focused on 
state-specific or county-level analysis. Previous research that 
analyzed variations in regional opioid use across the United 
States did show higher rates of opioid prescribing for pediatric 
and young adult patients in the western region of the United 
States, which includes the state of California, as compared 
to opioid prescribing rates in other areas of the country.(9) To 
better understand the use of opioids among pediatric and 
young adult patients in California, we conducted an analysis 
of publicly available data from the state’s controlled substance 
reporting system. The goal of the study was to examine county-
level trends in opioid prescribing in pediatrics and young adults 
in California from 2015 to 2019. The California Controlled 
Substance Utilization Review and Evaluation System (CURES) 
data, which is collected by the California Department of Justice 
(DOJ), was used for the analysis of the study.
Objective
The primary outcome of the study is to assess the changes 
in county-level opioid dispensing rates to pediatric and young 
adult patients in California from 2015-2019. A secondary 
outcome is identifying whether the presence of a pediatric 
hospital within the county impacts the likelihood the county 
is deemed a “high-rate” county, defined as having a high 
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Methods
CURES Database
The Controlled Substance Utilization Review and Evaluation 
System (CURES) is a prescription drug monitoring program 
that longitudinally tracks all Schedule II-IV controlled 
substance prescriptions dispensed in the state through 
California’s Department of Justice (DOJ). The DOJ provides 
aggregated reports to the general public based on the data 
collected through the CURES and makes them available 
online.(16) All data analysis conducted as part of this study were 
conducted using the aggregated datasets available from the 
publicly available online reports published from 2015-2019.(16)
California state law requires dispensing pharmacies, clinics, 
or other dispensers of Schedule II-IV controlled substances 
to provide specified dispensing information to the DOJ on a 
weekly basis. The patient’s identifiable information, such as 
name, date of birth, gender, and address, are also recorded, 
in addition to the prescriber and pharmacy identities with DEA 
registration numbers. The publicly available data provided by 
the DOJ used to conduct this research study are a series of 
limited datasets which have been deidentified and reported 
as aggregates based on various patient and provider factors. 
For example, metrics such as morphine milligram equivalents 
(MME) and pill counts were automatically calculated by CURES 
and prepared as composite data from the CA DOJ. This study 
is exempt from Institutional Review Board (IRB) approval, given 
the nature of the data analyzed. The public CURES database 
includes the number of patients receiving opioid prescriptions 
in a patients’ locale based upon the county, gender, age group 
(≤14 years, 15-24 years, 25-44 years, 45-64 years, and ≥65 
years), and year, from 2015 to 2019. To analyze how opioid 
dispensing rates are affected by the presence of children’s 
hospitals, these hospitals were identified using a directory 
available from the Children’s Hospital Association.(17)
Study Population
The CURES data used to complete the analysis of the study 
includes all information reported for opioid prescriptions 
dispensed in California. This data included reports of the 
number of patients dispensed opioids, broken up by the year, 
county, and preset age groupings. Stratification of age was 
maintained from the reported age groups in the DOJ’s publicly 
reported CURES statistics. All 58 counties in California were 
included in the study.
Study Outcome
The primary outcome of the study was the changes in county-
level opioid dispensing rates to pediatric and young adult 
patients in California from 2015-2019. Our secondary outcome 
was identifying whether the presence of a local pediatric 
hospital is associated with a county’s likelihood of being a 
“high-rate” county, defined as having a high magnitude of 
opioid prescriptions to pediatrics and young adults.
Statistical Analysis 
Descriptive statistics and heat maps were used to illustrate 
trends in opioid prescribing among different age groups and 
demographic regions and counties over the years studied. The 
total number of opioid prescriptions was collected from the 
datasets and analyzed in comparison to other demographic 
regions and counties in California. Opioid prescription trends 
were evaluated through three methods.
Overall rate of opioids dispensed to pediatric and young 
adult patients: First, the percentage of pediatric and young 
adults (<25 years old) dispensed opioids in each county was 
examined. “High-rate” counties were defined as counties 
that had a calculated percentage of opioid dispensing greater 
than 2.9% of the population, which is one standard deviation 
above the average rate reported in 2015, and is also the 
rate that marked the 80th percentile of counties in 2015. 
The trends were determined by comparing the heatmaps 
generated by different years.
Proportion of opioids dispensed to pediatrics and young 
adults: The next analysis examined the proportion of opioids 
prescribed to the pediatric and young adult population, 
comparing it to the total number of opioids prescribed in each 
county. Specifically, patients aged 15-24 years old in their 
respective counties were examined, broken down by year. 
Using the same method, the distribution of opioid prescriptions 
across each specific age group (≤14, 15-24, 25-44, 45-64, ≥65) 
in their respective county was visualized. Proportions of opioid 
prescriptions for each specific age group were calculated and 
demonstrated in the heatmap format using a color scale, 
where the red color represents the highest proportions seen. 
Prevalence of a pediatric hospital on opioid dispensing rate: 
The last point examined opioids dispensed to patients ≤14 
years old within the total population of the county. As in the 
first analysis, “high-rate” counties were defined by rates 
which were one standard deviation above the average rate 
reported in 2015, which was calculated to be 2.18%. These 
counties were highlighted in red and children’s hospital 
locations were identified and marked on the map.
Results
Based on census data, there were 37 million residents in 
California within our study time period, 2015-2019. During the 
individual years reported, the year of 2015 had the highest 
number of individual patients with an opioid prescription 
dispensed, with 7.12 million total patients receiving an opioid. 
In 2016, the number of patients with opioid prescriptions 
significantly decreased, with 4.81 million patients receiving an 
opioid (Table 1). Following the substantial reduction in overall 
number of patients being dispensed opioids from 2015 to 
2016, the number of patients remained relatively stable from 
2016 to 2019. In the final year of reporting, 5.01 million patients 
received an opioid in 2019. A similar trend also persisted when 
examining other metrics such as total morphine equivalent 
dose (MME) prescribed, CII-IV pill count, and total CII-IV 
prescription count per year. Notably, a higher quantity of CII 
pills and prescriptions were dispensed to the pediatric and 
young adult population each year compared to the amount 
of CIII-IV substances given to the same population (Table 1).
When evaluating patients younger than 25 years of age, 
similar patterns of dispensing were present. Similar to the 
overall statewide population, patients 24 years old or younger 
reported the largest number of patients dispensed an opioid 
in 2015 (780,630 patients), followed by a significant drop 
in patients dispensed an opioid in 2016 (473,764 patients), 
followed by a significant increase in 2017 (643,709 patients), 
and eventually noting a consistent decrease from 2018 
(537,197 patients) to 2019 (454,002 patients) (Table 1).
The number of “high-rate” counties for those aged <25 years 
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Table 1. Characteristics of the CURES database collected by the California Department of Justice from 2015-2019.
"-" means data not available based on the publicly-available databases posted online.
* the total population is based on US Census Data that was aggregated by the California Department of Justice and is representative 
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Comparing opioid dispensing rates on a county-level from 
2015-2019, counties overall reported reduced numbers of 
opioid prescriptions dispensed to patients younger than 25 
years. However, the rate of dispensing in central California 
counties persistently remained higher than that of other regions. 
In addition, at an overall state-level of reporting, as well as, 
within individual counties, there was an increase in the number 
of patients aged less than 25 years old being dispensed an 
opioid prescription from 2016 to 2017, followed by a steady 
decline afterwards. As shown in Table 1, the overall number of 
patients being dispensed an opioid has declined approximately 
10% and 11% per year on average among pediatric (≤14 years) 
and young adult (15-24 years old) patients, respectively.
When specifically evaluating the proportion of patients aged 
15-24 years old accounting for opioid prescriptions dispensed, 
this proportion has decreased each year since 2015, with 15-
24 years old accounting 9.38% of patients dispensed an opioid 
in 2015 dropping to 7.82% in 2019 (Figure 2). For this age 
group, higher proportions of dispensed opioids were observed 
in central and southern California than in other regions, with 
relatively fewer changes in the later years. Alpine County 
reported that 15.23% of individuals aged 15-24 were dispensed 
an opioid in 2015, the highest percentage of the state that year. 
The county with the lowest percentage was Trinity County, with 
a rate of 3.56% in 2019. The largest year over year proportion 
drop of any county was observed in Alpine Country from 2015 
– 2016, with a proportion of 15.23% in 2015 and 5.79% in 
2016 (an absolute proportion drop of 9.44%). However, Alpine 
also noted a significant surge in this proportion from 2016-
2017, increasing by an absolute proportion of 8.3%. Of note, 
given the high number of individuals aged 15-24 years having 
an opioid dispensed among residents, Alpine County also 
accounted for the highest proportion of opioids within this age 
group in every year of the analysis, with the exception of 2016.
Among all the opioid prescriptions, the amount of opioids 
dispensed to individuals aged 25 years and older was 
consistently higher than those under the age of 25 years old.; 
similar patterns were observed in every year examined (Figure 
3). The average percentage of opioids being dispensed to 
individuals ≤14 years old in 2015 was 1.63%, which is similar 
to the 1.25% recorded in 2019. The average percentage of 
total opioids dispensed to adolescents and young adults (15-
24 years old) in 2015 was 9.11%, with the actual percentage 
dropping to 7.29% in 2019 (Figure 2). Compared to other 
age groups, individuals ≤14 years old received the lowest 
percentage of opioid medications over the years (Figure 3). On 
average, approximately 27.2%, 37.5% and 24.6% of opioids 
prescriptions were dispensed to patients aged at 25-44, 45-
64, and 65+ years old respectively in 2015, and in 2019, those 
averages shifted to 23.46%, 35.91%, and 32.08% respectively.
For individuals aged 14 years old and younger, counties were 
deemed “high-rate” if the rate of opioids prescriptions given 
to these patients exceeded 2.18%, or one standard deviation 
above the average rate of opioids dispensed to patients in 
this age range (Figure 4). Rates were calculated as opioids 
dispensed per total population, and “high-rate” counties were 
marked in red. In 2015, there were seven identified “high-rate” 
counties for patients ≤14 years old. The following year, the total 
number of high-rate counties dropped to 3, and then increased 
back to 4 in 2017. By 2019 the number of “high-rate” counties 
had dropped to zero. Overall, most of the “high-rate” counties 
that had a prescription rates above 2.18% in individuals aged 
14 years old or younger were located in Central California.
When evaluating counties being deemed to be “high-rate” 
counties in relationship to opioid dispensing to individuals 
aged 14 years old or younger, none of the “high-rate” counties 
had a registered children’s hospital located within the county. 
Due to the absence of registered children’s hospitals in any of 
the “high-rate” counties, there was no possibility of running a 
statistical test to examine differences in opioid-use associated 
with the presence of a hospital from which to draw a conclusion. 
When evaluating the location of children’s hospitals and the 
relationship to opioid dispensing, there did not appear to be 
an association with higher rates of opioid dispensing among 
those aged 14 years old and less, as none of the “high-rate” 
counties contains a registered children’s hospital.
Discussion
In our study, we consistently observed a decline in opioid 
prescriptions from 2015 to 2016 among all patient populations 
recorded in California. The timing of this downtrend is 
consistent with trends reported nationally and coincides 
with the release of the updated CDC guidelines for opioid 
prescribing that encourage a general reduction in opioid use 
across most clinical situations.(7,9,18) To our knowledge, this 
is the first study examining county-level opioid dispensing 
in California within the time period of this study. Although 
studies examining national trends generally agree that the use 
of opioids in pediatric patients has overall decreased in recent 
years, there is uncertainty with how specific regions contribute 
to the trend – one study reported the western states with 
having the lowest prescribing rates(19), while another found 
the West to have the highest.(9) A notable point of observation 
is that the CDC guidelines exclude patients younger than 
18 years old; yet, our results suggest that patients younger 
than 18 have also experienced a decline in opioid prescribing 
after the publication of the updated CDC guidelines. It is 
uncertain to what degree that the guideline updates have 
affected opioid use in the pediatric, adolescent, and young 
adult population. However, it is likely that practitioners have 
interpreted these guidelines to suggest that opioids should be 
restricted for use in these populations in situations where no 
other pain management strategy is likely to achieve necessary 
pain reduction. Although it is not possible for us to validate 
any causes for the decline of opioid prescriptions based 
on the current CURES data, our study suggests that there 
may be a potential impact from the CDC guideline upon the 
decrease in opioid prescribing among pediatric patients given 
the congruence of the timeline. In addition, the results of our 
study suggest that following an initial sharp decline in the 
number of patients being prescribed an opioid from 2015 – 
2016, there was a significant rebound effect seen in 2017. This 
may be the result of practitioners reducing opioid prescribing 
too rapidly. The steady decline observed from 2017 through 
2019 suggests that practitioners once again made efforts to 
reduce opioid prescribing after the 2017 rebound.
This decline of opioid prescriptions among pediatric and young 
adults also aligned with the mandate for all California licensed 
prescribers to register for access to CURES by 2016, and for 
mandatory CURES consultations to start in 2018.(20) From 
January 2016 to January 2017, there was a 176% increase in 
registered CURES prescribers in California; within pharmacy, 
there was a 64% increase of pharmacists.(21) This and other 
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Figure 1. Opioid dispensing rates to patients younger than 25 years old (2015-2019).(16)*
County Abrv County Abrv County Abrv County Abrv County Abrv County Abrv
Alameda ALA Glenn GLE Marin MRN Placer PLA San Mateo SM Sutter SUT
Alpine ALP Humboldt HUM Mariposa MPA Plumas PLU Santa 
Barbara
SB Tehama TEH
Amador AMA Imperial IMP Mendocino MEN Riverside RIV Santa 
Clara
SCL Trinity TRI
Butte BUT Inyo INY Merced MER Sacramento SAC Santa Cruz SCR Tulare TUL
Calaveras CAL Kern KER Modoc MOD San Benito SBT Shasta SHA Tuolumne TUO
Colusa COL Kings KIN Mono MNO San Bernardino SBD Sierra SIE Ventura VEN
Contra Costa CC Lake LAK Monterey MON San Diego SD Siskiyou SIS Yolo YOL
Del Norte DN Lassen LAS Napa NAP San Francisco SF Solano SOL Yuba YUB
El Dorado ED Los 
Angeles
LA Nevada NEV San Joaquin SJ Sonoma SON
Fresno FRE Madera MAD Orange ORA San Luis 
Obispo
SLO Stanislaus STA
*Rates were calculated as total opioids dispensed per total population of the respective county.
*Proportions calculated as opioids dispensed to 15-24 year olds among total opioids dispensed per respective counties in California 
from 2015 to 2019.
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Figure 3. Comparison of opioids prescriptions among different age groups in 2015  and 2019 from data collected by DOJ.(16)* 
A) ≤14 years old; B) ≥ 65 years old.
A
B
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opioid prescribing may have contributed to the drop in opioid 
dispensing rates following the 2017 rebound. Similar reductions 
in opioid use were also observed in other studies which examined 
state opioid prescribing rates after the implementation of a 
prescription drug monitoring program (PDMPs).(22,23) Studies have 
also demonstrated a reduction in the prescribing of schedule II 
opioids after mandating registration to PDMPs.(24) While the initial 
intent of a PDMP is to reduce the number of prescriptions given 
to high-risk drug abusers by identifying patients who regularly 
fill controlled substances, there may have been a secondary 
effect where prescribers and dispensers adjusted their overall 
prescribing and dispensing practices due to the heightened 
awareness of PDMPs. 
In California, the total number of dispensed schedule II 
substances to pediatric and young adults also declined over 
the 4-year period, with the biggest drop occurring in 2016. 
The specific drug breakdown is not available with the given 
dataset, which restricts the ability to distinguish which of those 
schedule II substances dispensed were opioids. However, it 
was noted that a higher amount of schedule II substances 
was dispensed to the pediatric and young adult population, 
compared to the schedule III or IV substances. This may 
warrant further examination, as pediatric exposure to schedule 
II opioids has been shown to result in a higher likelihood of 
future alcohol use disorder, cannabis use disorder, or any other 
drug use disorder, compared to opioids belonging to "lower" 
scheduled controlled substance classes.(25)
Our study also revealed that there was a disproportionate 
decrease in opioids among the different age ranges. Patients 
older than 65 had the smallest degree of reduction in opioids 
dispensed, whereas pediatric and young adult patients had the 
some of the largest reduction rates. Thus, the fraction of total 
opioids dispensed to patients older than 65 increased, while 
the percentage dispensed to younger patients decreased. 
This trend suggests that there has been exceptional efforts in 
diminishing opioid use in age groups deemed at risk of misuse, 
namely, younger populations such as pediatrics and young 
adults. Meanwhile, older populations such as those above 65 
years old, may have persistently higher rates due to population 
characteristics such as more cases of palliative care and 
chronic pain. Opioid prescriptions for younger populations 
tend to treat acute issues such as surgical procedures and 
sport injuries – inherently, these medical issues tend to capture 
opioid naïve patients who are less likely to require a prolonged 
use of opioid compared to chronic pain patients. Therefore, the 
discrepancy observed in opioid prescribing among different 
age groups may be driven by the differences in their medical 
conditions that are typically experienced in each age group. 
Although the fraction of patients who received opioids at ages 
15-24 years old was relatively small compared to older age 
groups, providers should continue to be diligent with opioid 
use in this population due to concerns for misuse and abuse. 
The probability of prescription opioid abuse declines with 
increasing age at the first opioid exposure, with the peak risk 
being observed in patients using opioids for the first time as 
adolescents or young adults aged 18-24 years old.(26) This 
age group itself has been shown to be a risk factor for drug 
abuse(27,28), which only further compounds the problem.(29,30) 
Additionally, a previous study examining the CURES database 
found that younger patients and female patients were 
associated with using multiple prescribers and pharmacies 
for opioid prescriptions.(31) However, the data from this study 
is limited as it examines opioid prescriptions in 2006, which 
is significantly earlier than the data used in our study. Another 
study examining CURES opioid prescriptions from 1999 until 
2007 revealed that the highest increase of opioid use was 
among 18-44 year old females, whereas males aged 65 and 
older had the lowest rate of increase.(32) Juxtaposed with our 
study, which takes place during an overall effort to curb the 
opioid crisis, we observed an overall decline with the most 
change appearing to occur among patients younger than 25.
To our knowledge, few studies exist that examine county level 
factors in California that affect opioid prescribing. Since a 
large percentage of pediatric opioid prescribing comes from 
hospitals at discharge(33,34), we attempted to determine if the 
presence of a pediatric hospital would affect opioid prescribing 
rates. Our results found that none of the “high-rate” counties 
had a pediatric hospital, which may indicate that the presence 
of a pediatric hospital equipped with pediatric-specially 
trained providers may improve opioid prescribing practices. 
Additional studies are needed, as others have suggested that 
opioid prescribing practices between general and pediatric 
Figure 4. Children hospitals near the “high-rate” counties in CA from year 2015-2019.*
*Children hospital or specialty clinics were based on the information from the Children’s Hospital Association.(17) “High-rate” counties 
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hospitals are similar to one another.(35) Other sources of opioid 
prescriptions may be driving county-level factors, as there is a 
positive correlation between the number of available physicians 
within a patient’s residential county and number of prescribers 
and pharmacies that a patient uses per year.(36) In respect to 
national trends, one study examining congressional districts in 
2016 observed that Northern California, Eastern Arizona, and 
Nevada had relatively high opioid prescribing rates, second 
only to areas along the Appalachian and throughout the South.
(37) The same study also found that 3 of the 10 lowest rates were 
from regions in California. In addition, county-based factors 
such as median household income, average educational 
attainment, race/ethnicity, and physician availability may also 
significantly impact patient’s choice of multiple prescribers and 
pharmacies.(31) How this information translates to opioid use in 
pediatrics is unclear, and warrants further investigation. 
Another important consideration is the proportion of opioid 
prescriptions given per patient, as some opioid prescription 
rates may be driven by individuals receiving a substantial 
number of opioid prescriptions and those demonstrating 
drug-seeking behaviors, such as doctor-shopping. Our results 
show that less than 1% of patients are non-unique patients, 
but it is unclear how this number is distributed among those 
aged less than 25 years old. Additionally, non-unique patients 
who receive an opioid are not necessarily misusing opioids 
and may simply be managing more long-term pain disorders. 
Other studies examining CURES data has suggested that 
past rates of doctor shopping ranged from 1.25% to 5.31%, 
with the highest number being female patients older than 65; 
pediatric and young adult populations were not considered a 
high risk group.(32) Factors that affect multiple prescriber and 
pharmacy utilization among opioid users is understudied, 
but it is suspected that these factors may be similar to those 
that predict illicit drug use, such as psychological factors, 
socioeconomic status, and neighborhood disadvantage.(38-40) 
Seeking multiple prescribers may also be driven by clinically 
legitimate reasons, such as having multiple comorbidities 
that are treated by separate physicians, or suffering from 
undertreated pain due to the restricted opioid prescribing after 
the publication of the CDC guidelines.(41,42) Although our data 
does not reveal age-specific information related to individuals 
being dispensed multiple opioid prescriptions, it suggests 
that there remains a very low number of patients that are non-
unique opioid recipients in California from 2015 to 2019.
Ultimately, the tightening of opioid prescribing and dispensing 
is intended to improve public health outcomes and reduce 
overdose morbidity and mortality. According to the CDC, 
there was an overall reduction in deaths due to opioid 
prescriptions in California from 2014-2018.(43) Yet, deaths due 
to illicit and synthetic opioids have increased in the state, 
which have been driving up the overall opioid mortality rates. 
This is also mirrored on a national scale(3,4), which enforces 
the complexity of the opioid climate. Simply reducing opioid 
prescriptions does not improve the opioid mortality rate and 
further investigation is needed to identify effective research-
driven policies surrounding opioid use.(44,45)
Limitations
Given the retrospective, cross-sectional nature of the 
study, we are limited to reporting opioid prescribing rates 
and are restricted from conducting further predictive or 
causal analyses. While CURES data captures all controlled 
prescriptions that are dispensed through a pharmacy, it 
does not include federally regulated pharmacies, such as 
those under the jurisdiction of the Department of Defense 
and Indian Health Services. The application of our findings is 
also limited, as it lacks comparison to other states’ pediatric 
prescribing rates during the same studied time period. Further, 
not every pediatric-specific hospital may have been captured 
in this study, as it is not mandatory to join the Children’s 
Hospital Association. Another limitation of this study is its 
lack of analyzable variables that have been shown to affect 
opioid prescribing rates, such as sex/gender. This analysis 
was limited to the available information that was published 
on the CA DOJ website, which provided aggregate data sets 
with restricted manipulation. Therefore, we were unable to 
perform additional subgroup analyses and account for other 
demographic factors such as different age groupings, sex, 
race/ethnicity, and medication information (e.g. opioid name, 
quantity, and prescriber information). 
Conclusion
There has been an overall downtrend of pediatric and young 
adult patients on opioid prescriptions in California. Safer 
practices in this population should not be limited to reducing 
opioid prescriptions, as evidenced by the continued prevalence 
of opioid deaths despite the downtrend of prescribed opioids. 
Older adolescents and young adults are at risk of opioid 
misuse and abuse – identifying the environmental and intrinsic 
mechanisms that lead to this risk is essential, and targeting 
communities and regions with the higher risk may mitigate 
the issue substantially. Efforts aimed at public health policies 
should be specific and target at-risk populations, rather than 
be generalized, as this may prove ineffective.
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